Lipoprotein a lowering therapies Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines lipoprotein(a) lowering therapies, the RNA and oral medicines designed to cut the inherited blood particle that raises the risk of heart attack and stroke. It tests how the first cardiovascular outcome trial results reshape development, payer and prescribing decisions to 2034, and what that means for pharma firms, cardiologists and payers.
The first outcome result has arrived. On 4 September 2026 Novartis and Ionis announced that Lp(a)HORIZON, a trial of 8,323 patients with established cardiovascular disease and lipoprotein(a) of at least 70 mg/dL given pelacarsen 80 mg monthly, did not meet its primary endpoint. Full data presented on 7 November 2026 at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine showed lipoprotein(a) falling 78.4%, with no reduction in cardiovascular events after a median follow-up of 4.7 years. The conclusion is that lowering the particle by about four fifths was not enough to cut events in established disease, and the simple version of the hypothesis is not supported.
The next readouts test a deeper reduction. Amgen states that the OCEAN(a)-Outcomes trial of olpasiran in secondary prevention is ongoing, that OCEAN(a)-PreEvent in primary prevention and OCEAN(a)-CCTA on coronary plaque are enrolling, and gives no timing for data. Trial records place primary completion of OCEAN(a)-Outcomes in March 2028 and of Eli Lilly ACCLAIM-Lp(a) for lepodisiran in March 2029. The conclusion is that the question of whether a deeper and longer reduction helps will be answered between 2028 and 2029, so developers and payers face a period of waiting.
Interpretation is divided. Analysts at William Blair flagged meaningful risk to outcomes trials of the class, and Citi said it would not declare the mechanism dead. The conclusion is that investment and prescribing in the class now follow the olpasiran and lepodisiran readouts, and not the first result.
The brief treats lipoprotein(a) lowering therapies as a high-impact signal with an eight year horizon to 2034. It identifies which developers, diagnostics firms and payers capture value under each trial outcome. It is a focused 116-page decision brief that presents an indicative trajectory rather than a segmented market model.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2034 (8 years) |
| Emerging force | Lp(a) therapeutics |
| Technology readiness | No approved targeted therapy, with the first phase 3 outcome trial missed and two further outcome trials ongoing |
| Indicative market size & forecast | The lipoprotein(a) lowering therapies market, covering small interfering RNA, antisense and oral lipoprotein(a) inhibitors and lipoprotein apheresis for patients with elevated lipoprotein(a), and excluding LDL cholesterol, PCSK9 and other lipid-lowering therapies, is valued at USD 0.05–0.10 billion in 2026 and is projected to reach USD 1.28–2.56 billion by 2034, at a CAGR of 50% |
| Mainstream inflection | ~2031, when the olpasiran and lepodisiran outcome trials have read out and any positive result reaches approval and payer coverage |
| Signal strength | A missed first outcome trial and two pending outcome trials, against limited evidence on deeper reduction |
| Primary beneficiaries | Developers with positive outcome data; diagnostics firms measuring lipoprotein(a); apheresis providers serving patients with high levels; payers with clear coverage criteria |
| Brief length / format | 116 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
Lipoprotein(a) is a particle that carries cholesterol and a protein called apolipoprotein(a), and its level is set largely by genes. High levels are linked to heart attack, stroke and aortic valve disease, and standard lipid medicines lower it little. The conclusion is that patients with high levels have had no targeted option, which is the gap these therapies address.
The leading medicines silence production of the protein in the liver. Pelacarsen is an antisense medicine given monthly, and olpasiran and lepodisiran are small interfering RNA medicines given at longer intervals. Phase 2 results for olpasiran and lepodisiran showed placebo-adjusted reductions close to the full level, against about 35% to 80% across doses for pelacarsen. The conclusion is that the later trials test a deeper reduction than the first.
Pelacarsen has now reduced lipoprotein(a) by 78.4% without reducing events. Genetic studies estimate that a large absolute fall is needed to match the benefit of lowering LDL cholesterol, and lifelong exposure may differ from late treatment in established disease. The conclusion is that depth of reduction, timing in life and patient selection are open questions for the next trials.
The limits are trial risk, long event-driven timelines, the cost of outcome trials and the lack of a proven benefit. The brief tests each limit against the evidence to 2034.
Market Outlook
The lipoprotein(a) lowering therapies market, covering small interfering RNA, antisense and oral lipoprotein(a) inhibitors and lipoprotein apheresis for patients with elevated lipoprotein(a), and excluding LDL cholesterol, PCSK9 and other lipid-lowering therapies, is valued at USD 0.05–0.10 billion in 2026 and is projected to reach USD 1.28–2.56 billion by 2034, at a CAGR of 50%.
The 2026 base rests on lipoprotein apheresis for patients with elevated lipoprotein(a) and early use of targeted therapies in trials and access programmes, at current prices, which excludes LDL cholesterol, PCSK9 and other lipid-lowering therapies. Growth follows the outcome trial results, approval timing, the number of patients with elevated lipoprotein(a) who are identified and the price per patient year.
The forecast is sensitive to the olpasiran and lepodisiran results, regulatory decisions, payer coverage and the scale of lipoprotein(a) testing.
Scenarios
Scenarios.
The base case assumes at least one of the next outcome trials shows benefit, with approval around 2030 and coverage in 2031, bringing the inflection to 2031 and a 2034 value near the middle of the range. An accelerated case assumes an early positive olpasiran result and fast approval, moving the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes the later trials also fail or read out late, moving the inflection beyond 2034 and holding value at the bottom of the range.
Factors Behind Growth
Growth drivers
- Large population with elevated lipoprotein(a).
- No targeted therapy for patients with high levels.
- Deeper reducing medicines in outcome trials.
- Growing lipoprotein(a) testing.
Enablers
- Large outcome trials in secondary and primary prevention.
- Long-acting RNA medicines.
- Guideline interest in measuring lipoprotein(a).
- Royalty and partnership financing of development.
Restraints and barriers
- First outcome trial missed its primary endpoint.
- Long and costly event-driven trials.
- Payer need for outcome evidence.
- Uncertainty over the level and timing of reduction needed.
The Forces at Play
The direction of lipoprotein(a) lowering therapies is set by outcome trial results, regulatory decisions, payer coverage and the scale of testing.
The brief assesses standards and policy, company and investor funding, technology readiness, product readiness and customer readiness, and rates each force for direction, speed and confidence.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
Developers and payers reassess the class after the first outcome result while testing expands.
Olpasiran and lepodisiran outcome results decide whether the class reaches approval.
Positive results lead to launches and coverage, and negative results lead to exit or narrow use.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| Feb 2019 | Novartis takes the licence option for pelacarsen from Ionis | Licensing | Funds the first outcome trial |
| Aug 2023 | Novartis and Ionis sign a next-generation Lp(a) collaboration with a USD 60 million upfront payment | Collaboration | Extends the class with a second programme |
| Sep 2025 | The design of Lp(a)HORIZON is published in the American Heart Journal | Publication | Sets the outcome trial design on record |
| Sep 2026 | Novartis and Ionis report that Lp(a)HORIZON did not meet its primary endpoint | Trial result | First outcome result for the class |
| Nov 2026 | Amgen reports OCEAN(a)-Outcomes ongoing and OCEAN(a)-PreEvent and OCEAN(a)-CCTA enrolling | Update | Confirms next outcome trials continue |
| Nov 2026 | Full Lp(a)HORIZON data are presented at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine | Trial result | Gives the first full outcome dataset |
Key Players & Competitive Landscape
The key participants in lipoprotein(a) lowering therapies include Novartis AG, Ionis Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company, Silence Therapeutics plc, Arrowhead Pharmaceuticals, Inc., Royalty Pharma plc, Merck & Co., Inc., AstraZeneca PLC, Novo Nordisk A/S, Pfizer Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Esperion Therapeutics, Inc., NewAmsterdam Pharma Company N.V., Kaneka Corporation, Fresenius Medical Care AG, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, among others.
The brief profiles representative participants in each archetype and assesses which are positioned to lead under each outcome trial scenario.
Competitive intensity is low among Lp(a) developers today and rises sharply if outcome trials succeed, with entry barriers set by outcome trial size, manufacturing of RNA medicines and payer evidence.
| Archetype | Representative players | Position in 2026 | Outlook to 2034 |
|---|---|---|---|
| Lp(a) developers with outcome trials | Novartis AG, Ionis Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company, Silence Therapeutics plc, Arrowhead Pharmaceuticals, Inc. | Antisense, small interfering RNA and oral Lp(a) inhibitors | Complete outcome trials and prepare launch |
| Royalty and financing firms | Royalty Pharma plc | Development financing | Fund trials against royalties |
| Lipid therapy incumbents | Merck & Co., Inc., AstraZeneca PLC, Novo Nordisk A/S, Pfizer Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Esperion Therapeutics, Inc., NewAmsterdam Pharma Company N.V. | LDL cholesterol and cardiovascular medicines | Compete for the cardiovascular prevention budget |
| Apheresis providers | Kaneka Corporation, Fresenius Medical Care AG | Lipoprotein apheresis | Serve patients with very high levels |
| Diagnostics firms | Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings | Lipoprotein(a) testing | Identify patients with elevated levels |
Where value migrates.
In 2026 value sits with developers holding outcome trials and with testing and apheresis providers serving patients today. By 2031 it moves toward the developers with positive results and toward payers that set coverage criteria. By 2034 it settles with the one or two medicines with proven benefit and the diagnostics that find eligible patients, or it leaves the class if outcome trials fail. Margins follow the evidence.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Proven benefit unlocks approval and coverage.
Testing finds eligible patients.
Clear criteria limit spend to proven benefit.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| Novartis and Ionis | Lp(a)HORIZON primary endpoint not met | September 2026 | First outcome result for the class |
| American Heart Association Scientific Sessions | Full Lp(a)HORIZON data presented with simultaneous publication | November 2026 | Gives the first full outcome dataset |
| Amgen | OCEAN(a)-Outcomes ongoing, with primary completion in March 2028 | March 2028 | Next outcome result |
| Amgen | OCEAN(a)-PreEvent enrolling in primary prevention | 2026 | Tests earlier treatment |
| Eli Lilly | ACCLAIM-Lp(a) with primary completion in March 2029 | March 2029 | Third outcome result |
Investment Signals
The large population with high lipoprotein(a), the lack of targeted therapy, deeper reducing medicines and growing testing support growth, while the missed first outcome trial, long trial timelines, payer demand for outcome evidence and uncertainty over the reduction needed hold back the pace.
The olpasiran readout, the lepodisiran readout, subgroup analysis of Lp(a)HORIZON or a guideline change would shift the pace. The brief therefore tracks four indicators: outcome trial results, regulatory filings, payer coverage and testing volumes.
Reassessment, then second readouts, then evidence-led adoption is the expected order of change.
Questions This Brief Answers
Strategic Implications
- Pharma firms: weigh trial spend against the olpasiran and lepodisiran readouts and plan launch only after positive outcome data.
- Cardiologists: measure lipoprotein(a) once and treat high values through apoB and LDL cholesterol lowering until outcome evidence arrives.
- Payers: set coverage criteria that wait for outcome data and define the eligible patient group early.
- Diagnostics and apheresis providers: scale testing and prepare for a change in eligible patient numbers under each trial outcome.
- Investors: treat the class as binary on the next two readouts, and size positions to the timing of March 2028 and March 2029.
"A particle can be lowered by four fifths and still not move the event count."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief